Abiopharma

🔍 Sheena Jonathan (Executive)

Company: Natera, Inc. (NTRA)

Report Date: 2025-10-27

Detailed Transactions and Holdings:

• Sold 288 shares of Common Stock at $192.324 per share (Direct)
  Date: 2025-10-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 235,921.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 191 shares of Common Stock at $191.4619 per share (Direct)
  Date: 2025-10-28 | Code: S | equity_swap_involved: 0 | shares_owned_after: 235,730.00 | transaction_form_type: 4 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-10-27 | Code: H | nature_of_ownership: By Caraluna 1 Trust | shares_owned_after: 28,032.00 | Footnotes: F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-10-27 | Code: H | nature_of_ownership: By Caraluna 2 Trust | shares_owned_after: 28,032.00 | Footnotes: F3

Footnotes:

• F1: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 26, 2024.
• F2: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 27, 2023.
• F3: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.